Novartis, Venter team on faster vax development

Novartis is turning to J. Craig Venter to help blaze a development shortcut that can carve weeks out of the time it takes to ramp up production of a new flu vaccine. One of the bottlenecks that appeared while developing a vaccine to fight swine flu occurred as the World Health Organization identified and distributed a reference virus needed to create new jabs. Venter's Synthetic Genomics Vaccines--a newly launched subsidiary--will work with Novartis to produce synthetic seed viruses, cutting as much as two months out of the development timeline. Story

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.